These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 20439529)

  • 1. Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study.
    Bastian H; Zinke S; Egerer K; Breuer S; Safari F; Burmester GR; Feist E
    J Rheumatol; 2010 May; 37(5):1069-71. PubMed ID: 20439529
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial.
    Mease PJ; Cohen S; Gaylis NB; Chubick A; Kaell AT; Greenwald M; Agarwal S; Yin M; Kelman A
    J Rheumatol; 2010 May; 37(5):917-27. PubMed ID: 20194448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab therapy in rheumatoid arthritis in daily practice.
    Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
    J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.
    Teng YK; Tekstra J; Breedveld FC; Lafeber F; Bijlsma JW; van Laar JM
    Ann Rheum Dis; 2009 Jun; 68(6):1075-7. PubMed ID: 19435725
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab therapy in patients with rheumatoid arthritis refractory or with contraindication to anti-tumour necrosis factor drugs: real-life experience in Finnish patients.
    Valleala H; Korpela M; Möttönen T; Hienonen-Kempas T; Kauppi M; Hannonen P; Leirisalo-Repo M
    Scand J Rheumatol; 2009; 38(5):323-7. PubMed ID: 19585384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience.
    Jois RN; Masding A; Somerville M; Gaffney K; Scott DG
    Rheumatology (Oxford); 2007 Jun; 46(6):980-2. PubMed ID: 17384180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single course of rituximab does not abrogate anti-infliximab antibodies in patients with rheumatoid arthritis.
    van den Bemt BJ; Vos K; den Broeder AA; Blom M; Thurlings RM; Bartelds GM; Stapel SO; Barrera P; Tak PP; Nurmohamed MT; Wolbink GJ
    Ann Rheum Dis; 2009 Aug; 68(8):1368-9. PubMed ID: 19605744
    [No Abstract]   [Full Text] [Related]  

  • 8. Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis.
    Risselada A; Tekstra J; Teng YK; Welsing PM; Breedveld F; van Laar JM; Bijlsma JW
    Ann Rheum Dis; 2010 Oct; 69(10):1891-2. PubMed ID: 20444758
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
    Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
    Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long term treatment of rheumatoid arthritis with rituximab.
    Caporali R; Caprioli M; Bobbio-Pallavicini F; Bugatti S; Montecucco C
    Autoimmun Rev; 2009 Jun; 8(7):591-4. PubMed ID: 19393205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for treatment of scleritis associated with rheumatoid arthritis.
    Chauhan S; Kamal A; Thompson RN; Estrach C; Moots RJ
    Br J Ophthalmol; 2009 Jul; 93(7):984-5. PubMed ID: 19553514
    [No Abstract]   [Full Text] [Related]  

  • 12. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics.
    Renato GM
    Ann N Y Acad Sci; 2009 Sep; 1173():729-35. PubMed ID: 19758222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of monoclonal antibodies to tumor necrosis factor (remicade) in rheumatoid arthritis: preliminary results].
    Lukina GV; Sigidin IaA; Chichasova NV; Balabanova RM; Belenkiĭ AG; Imametdinova GR; Barskova VG; Bochkova AG; Gukasian DA; Egorova ON; Karateev DE; Kolosova IR; Loginova EIu; Pudovkina EIu; Stanislav ML; Taukumova LA; Fedina TP; Nasonov EL
    Ter Arkh; 2003; 75(5):9-12. PubMed ID: 12847890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.
    Vos K; Thurlings RM; Wijbrandts CA; van Schaardenburg D; Gerlag DM; Tak PP
    Arthritis Rheum; 2007 Mar; 56(3):772-8. PubMed ID: 17328049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

  • 16. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept.
    Buch MH; Seto Y; Bingham SJ; Bejarano V; Bryer D; White J; Emery P
    Arthritis Rheum; 2005 Jan; 52(1):42-8. PubMed ID: 15641046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Rituximab (Mabthera)--treatment of rheumatoid arthritis patients with inadequate response to TNF inhibitors--when to change therapy?].
    Morović-Vergles J
    Reumatizam; 2008; 55(2):70-2. PubMed ID: 19024280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-tumour necrosis factor alpha therapy modulates ghrelin in patients with severe rheumatoid arthritis.
    Gonzalez-Gay MA; Garcia-Unzueta MT; Berja A; Vazquez-Rodriguez TR; Gonzalez-Juanatey C; de Matias JM; Martin J; Dessein PH; Llorca J
    Ann Rheum Dis; 2008 Nov; 67(11):1644-6. PubMed ID: 18854515
    [No Abstract]   [Full Text] [Related]  

  • 19. Successful treatment of rheumatoid vasculitis-associated cutaneous ulcers using rituximab in two patients with rheumatoid arthritis.
    Hellmann M; Jung N; Owczarczyk K; Hallek M; Rubbert A
    Rheumatology (Oxford); 2008 Jun; 47(6):929-30. PubMed ID: 18411212
    [No Abstract]   [Full Text] [Related]  

  • 20. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.
    Popa C; Leandro MJ; Cambridge G; Edwards JC
    Rheumatology (Oxford); 2007 Apr; 46(4):626-30. PubMed ID: 17189244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.